Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Completes Enrollment in Cancer Drug Trial

Premium

Alnylam Pharmaceuticals said this week that it has completed enrollment in a phase I trial of its siRNA-based cancer drug ALN-VSP.

ALN-VSP was administered to more than 40 patients with advanced solid tumors with liver involvement at doses ranging from 0.1 to 1.5 mg/kg, with multiple patients continuing to receive therapy on the study, the company said.

Data are scheduled to be presented at the American Society of Clinical Oncology meeting in Chicago June 3 to 7.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.